Natera, Inc.
NTRA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 3 days ago • NTRA
Natera to Report its First Quarter Results on May 7, 2026
Business Wire • 11 days ago • NTRA
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Benzinga • 19 days ago • NTRA
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
Benzinga • about a month ago • NTRA
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Business Wire • about a month ago • NTRA
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.